Table 1 Clinical and demographic features of COVID-19 patients in Shiraz, South of Iran
Variable | Total (%) n = 113 | Severe n = 11 | Non-severe n = 102 | P.value | Deathn = 9 | Liven = 104 | P.value |
|---|---|---|---|---|---|---|---|
Age (years) | |||||||
 20–34 | 13 (11.5) | 1 (7.7) | 12 (92.3) | 0.750 | 1 (7.7) | 12 (92.3) | 0.899 |
 35–49 | 36 (31.9) | 2 (5.6) | 34 (94.4) | 2 (5.6) | 34 (94.4) | ||
 50–64 | 36 (31.9) | 5 (13.9) | 31 (86.1) | 3 (8.3) | 33 (91.7) | ||
 65–74 | 14 (12.4) | 2 (14.3) | 12 (85.7) | 1 (7.1) | 13 (92.9) | ||
  ≥ 75 | 14 (12.4) | 1 (7.1) | 13 (92.9) | 2 (14.3) | 12 (85.7) | ||
Sex | |||||||
 Male | 71 (62.8) | 7 (9.9) | 64 (90.1) | 0.750 | 5 (7) | 66 (93) | 0.725 |
 Female | 42 (37.2) | 4 (9.5) | 38 (90.5) | 4 (9.5) | 38 (90.5) | ||
Occupation | |||||||
 Healthcare worker | 3 (2.8) | 0 (0) | 3 (100) | 1.000 | 0 (0) | 3 (100) | 1.000 |
 Non-healthcare worker | 103 (97.2) | 9 (8.7) | 94 (91.3) | 9 (8.7) | 94 (91.3) | ||
History of Contact with infected cases | 19 (16.8) | 0 (0) | 19 (100) | 0.206 | 0 (0) | 19 (100) | 0.353 |
History of travelling | 30 (26.5) | 3 (10) | 27 (90) | 1.000 | 2 (6.7) | 28 (93.3) | 1.000 |
Comorbid Disease | |||||||
 Hypertension | 22 (19.5) | 5 (22.7) | 17 (77.3) | 0.037 | 2 (9.1) | 20 (90.9) | 1.000 |
 Diabetes | 16 (14.2) | 3 (18.8) | 13 (81.3) | 0.188 | 2 (12.5) | 14 (87.5) | 0.613 |
 Cardiovascular disease | 16 (14.2) | 4 (25) | 12 (75) | 0.049 | 2 (12.5) | 14 (87.5) | 0.613 |
 Malignancy | 1 (0.9) | 0 (0) | 1 (100) | 1.000 | 0 (0) | 1 (100) | 1.000 |
 Asthma | 7 (6.2) | 1 (14.3) | 6 (85.7) | 0.522 | 1 (14.3) | 6 (85.7) | 0.450 |
 Chronic obstructive Pulmonary disease | 9 (8.0) | 1 (11.1) | 8 (88.9) | 1.000 | 1 (11.1) | 8 (88.9) | 0.540 |
 Chronic kidney disease | 6 (5.3) | 0 (0) | 6 (100) | 1.000 | 0 (0) | 6 (100) | 1.000 |
 Other Immunosuppressive diseases | 2 (1.8) | 0 (0) | 2 (100) | 1.000 | 0 (0) | 2 (100) | 1.000 |
Symptoms at onset of illness | |||||||
 Fever | 67 (59.3) | 5 (7.5) | 62 (92.5) | 0.350 | 3 (4.5) | 64 (95.5) | 0.156 |
 Cough | 73 (64.6) | 5 (6.8) | 68 (93.2) | 0.193 | 5 (6.8) | 68 (93.2) | 0.718 |
 Fatigue | 75 (66.4) | 10 (13.3) | 65 (86.7) | 0.096 | 8 (10.7) | 67 (89.3) | 0.268 |
 Sputum production | 24 (21.4) | 2 (8.3) | 22 (91.7) | 1.000 | 4 (16.7) | 20 (83.3) | 0.097 |
 Dyspnea | 58 (51.3) | 8 (13.8) | 50 (86.2) | 0.205 | 4 (6.9) | 54 (93.1) | 0.738 |
 Chest pain | 43 (38.1) | 6 (14) | 37 (86) | 0.328 | 3 (7) | 40 (93) | 1.000 |
 Chills | 67 (59.3) | 4 (6) | 63 (94) | 0.114 | 3 (4.5) | 64 (95.5) | 0.153 |
 Hemoptysis | 7 (6.2) | 0 (0) | 7 (100) | 1.000 | 0 (0) | 7 (100) | 1.000 |
 Rhinorrhea | 26 (23.0) | 1 (3.8) | 25 (96.2) | 0.452 | 2 (7.7) | 24 (92.3) | 1.000 |
 Sore throat | 36 (31.9) | 3 (8.3) | 33 (91.7) | 1.000 | 2 (5.6) | 34 (94.4) | 0.716 |
 Abdominal pain | 24 (21.2) | 2 (8.3) | 22 (91.7) | 1.000 | 2 (8.3) | 22 (91.7) | 1.000 |
 Diarrhea | 25 (22.1) | 1 (4) | 24 (96) | 0.451 | 2 (8) | 23 (92) | 1.000 |
 Nausea | 48 (42.5) | 5 (10.4) | 43 (89.6) | 1.000 | 5 (10.4) | 43 (89.6) | 0.491 |
 Vomiting | 29 (25.7) | 2 (6.9) | 27 (93.1) | 0.725 | 4 (13.8) | 25 (86.2) | 0.234 |
 Anorexia | 75 (66.4) | 9 (12) | 66 (88) | 0.329 | 8 (10.7) | 67 (89.3) | 0.268 |
 Myalgia /Arthralgia | 69 (61.1) | 7 (10.1) | 62 (89.9) | 1.000 | 5 (7.2) | 64 (92.8) | 0.734 |
 Headache | 60 (53.1) | 5 (8.3) | 55 (91.7) | 0.753 | 6 (10) | 54 (90) | 0.498 |
 Dizziness/ Vertigo | 45 (39.8) | 7 (15.6) | 38 (84.4) | 0.111 | 6 (13.3) | 39 (86.7) | 0.152 |
 Conjunctival congestion | 17 (15.0) | 2 (11.8) | 15 (88.2) | 0.670 | 2 (11.8) | 15 (88.2) | 0.622 |
Physical exam on admission | |||||||
Temperature | |||||||
   < 37.3 | 77 (68.1) | 8 (10.4) | 69 (89.6) | 0.005 | 6 (7.8) | 71 (92.2) | 0.002 |
  37.3–38 | 24 (21.2) | 0 (0) | 24 (100) | 0 (0) | 24 (100) | ||
  38.1–39 | 11 (9.7) | 2 (18.2) | 9 (81.8) | 2 (18.2) | 9 (81.8) | ||
   > 39 | 1 (0.9) | 1 (0.9) | 0 (0) | 1 (100) | 0 (0) | ||
Heart Rate | |||||||
   > 100 (beats/min) | 12 (10.6) | 1 (7.7) | 12 (92.3) | 1.000 | 1 (7.7) | 12 (92.3) | 1.000 |
Respiratory Rate | |||||||
   > 24(breaths/min) | 2 (1.8) | 1 (50) | 1 (50) | 0.186 | 1 (50) | 1 (50) | 0.154 |
Blood Pressure | |||||||
  Normal | 36 (32.4) | 4 (11.1) | 32 (88.9) | 0.738 | 4 (11.1) | 32 (88.9) | 0.617 |
  Elevated | 7 (6.3) | 7 (10) | 63 (90) | 5 (7.1) | 65 (92.9) | ||
Saturation of O2 | |||||||
   < 90 | 39 (34.5) | 7 (17.9) | 32 (82.1) | 0.046a | 4 (5.4) | 70 (94.6) | 0.271 |
   ≥ 90 | 74 (65.5) | 4 (5.4) | 70 (94.6) | 5 (12.8) | 34 (87.2) | ||
Lung Auscultation | |||||||
  Respiratory Rales | 27 (23.9) | 7 (25.9) | 20 (74.1) | 0.004a | 3 (11.1) | 24.(88.9) | 0.444 |
  Respiratory Wheeze | 8 (7.1) | 0 (0) | 8 (100) | 1.000 | 0 (0) | 8 (100) | 1.000 |
  Respiratory Stridor | 10 (8.8) | 1 (10) | 9 (90) | 1.000 | 1 (10) | 9 (90) | 0.580 |
Other Infection Signs | |||||||
  Throat Congestion | 17 (15.0) | 4 (23.5) | 13 (76.5) | 0.060 | 1 (5.9) | 16 (94.1) | 1.000 |
  Swelling of tonsils | 8 (7.1) | 1 (12.5) | 7 (87.5) | 0.571 | 0 (0) | 8 (100) | 1.000 |
  Lymphadenopathy | 3 (2.7) | 1 (33.3) | 2 (66.7) | 0.267 | 0 (0) | 3 (100) | 1.000 |
  Rash | 6 (5.3) | 0 (0) | 6 (100) | 1.000 | 1 (16.7) | 5 (83.3) | 0.377 |
Treatment | |||||||
  Anti-Viral therapy | 113 (100.0) | 11 (9.7) | 102 (90.3) | NA | 9 (8) | 104 (92) | NA |
  Antibiotic therapy | 112 (99.1) | 11 (9.8) | 101 (90.2) | 1.000 | 9 (8) | 103 (92) | 1.000 |
  Use of Corticosteroid | 5 (4.4) | 2 (40) | 3 (60) | 0.074 | 1 (20) | 4 (80) | 0.345 |
Oxygen support | |||||||
  Nasal cannula | 31 (27.4) | 1 (3.2) | 30 (96.8) | 0.285 | 1 (3.2) | 30 (96.8) | 0.440 |
  Noninvasive ventilation or high flow mask | 11 (9.8) | 6 (54.5) | 5 (45.5) | 0.000a | 1 (9.1) | 10 (90.9) | 1.000 |
  Invasive mechanical ventilation | 2 (1.8) | 2 (100) | 0.000 | 0.009a | 2 (100) | 0 (0) | 0.006a |
Prognosis | |||||||
  Hospitalization | 29 (25.7) | 2 (6.9) | 27 (93.1) | 0.000a | 0 (0) | 29 (100) | 0.000a |
  Discharge with continued OPD treatment | 7 (6.2) | 1 (14.3) | 6 (85.7) | 0 (0) | 7 (100) | ||
  Total Recovery | 68 (60.2) | 3 (4.4) | 65 (95.6) | 0 (0) | 68 (100) | ||
  Death in course of Hospitalization | 9 (8) | 5 (55.6) | 4 (44.4) | 9 (100) | 0 (0) | ||